Fig. 2.

Evobrutinib inhibits the maturation of B cells. Oral treatment of C57/BL6 mice with vehicle or 1, 3 or 10 mg/kg evobrutinib started 7 days prior to immunization with 75 µg conformational MOG1-117 protein. Single cell suspensions of the secondary immune organs were analyzed 12 days after immunization by flow cytometry. a, b B-cell subsets were categorized into transitional (T), follicular (FO), marginal zone precursor (MZP) and marginal zone (MZ) cells. Frequency of B220⁺ cells is shown for c blood, d spleen, e inguinal lymph node and f cervical lymph node. Median, n = 8–16 pooled from 4 to 8 independent experiments, **p < 0.01, ****p < 0.0001